Nanologica has entered the insulin market in China with an order of approximately SEK 2 million for the company's silica-based purification media NLAB Saga®. The customer is an insulin manufacturer and the order relates to evaluation of NLAB Saga® on a production scale.
This is Nanologica's first order regarding evaluation of NLAB Saga® for insulin manufacturing on the Chinese market. Nanologica’s team has worked with this customer for a few years and the customer has now acknowledged Nanologica’s products and expertise and are now moving forward to evaluate NLAB Saga® on a manufacturing scale with the purpose of including it in its manufacturing.
"After having received a number of orders regarding NLAB Saga® for the production of GLP-1 analogues, it is now very gratifying to receive this order for insulin production. Initially, we built our case and our production line to be able to supply silica to insulin manufacturers. This order is a big step in the right direction and indicates that we will be able to sell our various product types and not just the one generally used for purification of GLP-1 analogues. Our team has done a tremendous job with this customer who is now opening up for changing their process as they see we can help them lower their manufacturing costs. We have the now requested product type in stock and we will thus be able to deliver immediately against this order", comments Nanologica's CEO Andreas Bhagwani.
The order value is approximately SEK 2 million at today's exchange rate and will be delivered immediately.